NOUVEAU COMPOSE AYANT LA CAPACITE A INHIBER L'ENZYME 11B-HSD1 OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, PROCEDE DE PRODUCTION ASSOCIE, ET COMPOSITION PHARMACEUTIQUE CONTENANT CELUI-CI EN TANT QUE PRINCIPE ACTIF
AHN-GOOK PHARMACEUTICAL CO., LTD.;BAMICHEM CO., LTD.;INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
发明人:
HAN, CHEOL KYU,AUH, JIN,CHOI, NAM SONG,HAN, CHANG KYUN,KIM, TAE-JEONG,PAE, KAMSA,SHIN, YOUNG JUNE,HAN, DONG-OH,AHN, SOON KIL
申请号：
CA2876584
公开号：
CA2876584C
申请日:
2013.06.04
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
The present invention relates to a novel compound having the ability to inhibit the 11ß-HSD1 enzyme or to a pharmaceutically acceptable salt thereof, to a method for producing same, and to a pharmaceutical composition containing same as an active ingredient. The compound according to the present invention selectively inhibits the activity of 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1), and can thus be effectively used as a therapeutic agent for treating diseases caused by the excessive activity of 11ß-HSD1, e.g. non-insulin dependent (type 2) diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and diseases and conditions brought on by the excessive activity of glucocorticoids.
